Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 1/20 | 0.44 |
| ▸ | METAP1 | P53582 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | CTSC | P53634 | 2/20 | 0.41 |
| ▸ | DPP4 | P27487 | 4/20 | 0.41 |
| ▸ | DPP8 | Q6V1X1 | 4/20 | 0.41 |
| ▸ | DPP9 | Q86TI2 | 4/20 | 0.41 |
| ▸ | FNTA | P49354 | 3/20 | 0.39 |
| ▸ | FNTB | P49356 | 3/20 | 0.39 |
| ▸ | PGGT1B | P53609 | 2/20 | 0.39 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.38 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.38 |
| ▸ | BHMT | Q93088 | 1/20 | 0.37 |
| ▸ | BHMT2 | Q9H2M3 | 1/20 | 0.37 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.37 |
| ▸ | ANPEP | P15144 | 1/20 | 0.36 |
| ▸ | ENPEP | Q07075 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14065663 | 1.00 | METAP2 (0.44) | METAP2METAP1LMNATSHRCTSC | |
| SCHEMBL13444880 | 0.87 | METAP2 (0.43) | METAP2METAP1LMNATSHRCTSC | |
| SCHEMBL13444876 | 0.87 | METAP2 (0.43) | METAP2METAP1LMNATSHRCTSC | |
| SCHEMBL2875974 | 0.84 | METAP2 (0.48) | METAP2METAP1LMNACTSCDPP4 | |
| SCHEMBL8936813 | 0.84 | METAP2 (0.48) | METAP2METAP1LMNACTSCDPP4 | |
| SCHEMBL8661911 | 0.84 | METAP2 (0.48) | METAP2METAP1LMNACTSCDPP4 | |
| SCHEMBL9352805 | 0.82 | CTSC (0.41) | METAP2METAP1LMNATSHRCTSC | |
| SCHEMBL9352804 | 0.82 | CTSC (0.41) | METAP2METAP1LMNATSHRCTSC | |
| SCHEMBL17746783 | 0.82 | SLC15A1 (0.48) | METAP2METAP1LMNATSHRCTSC | |
| SCHEMBL30051498 | 0.81 | METAP2 (0.46) | METAP2METAP1LMNACTSCDPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230072658-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-03-09 | — | — | US | disclosed |
| US-7419990-B2 | Piperidine derivatives as melanocortin-4 receptor agonists | MERCK & CO., INC. (US) | 2008-09-02 | — | — | US | disclosed |
| US-7419990-B2 | Piperidine derivatives as melanocortin-4 receptor agonists | MERCK & CO., INC. (US) | 2008-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230072658-A1 | SMARCA DEGRADERS AND USES THEREOF | SMARCA1, SMARCB1, SMARCE1 | METAP2 3958/4885METAP1 3060/4885LMNA 621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.